INDEX for Abraxis_BioScience (ABII)

Send us Feedback

Abraxis BioScience (ABII)

	SUMMARY

	BULLS

	BEARS

	TOPICS

	DATA CENTRAL

	STOCK CHART

	SEC FILINGS

	BALANCE

	INCOME

	CASH FLOW

ABII » Topics » INDEX

This excerpt taken from the ABII 10-Q filed May 8, 2009.

INDEX


		Page

PART I. Financial Information

Item 1.	Financial Statements (Unaudited)	3

	Condensed consolidated balance sheets – March 31, 2009 and December 31, 2008	3

	Condensed consolidated statements of operations – Three months ended March 31, 2009 and 2008	4

	Condensed consolidated statements of cash flows – Three months ended March 31, 2009 and 2008	5

	Notes to unaudited condensed consolidated financial statements – March 31, 2009	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	18

Item 4.	Controls and Procedures	19

PART II. Other Information

Item 1.	Legal Proceedings	20

Item 1A.	Risk Factors	20

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	30

Item 3.	Defaults Upon Senior Securities	30

Item 4.	Submission of Matters to a Vote of Security Holders	30

Item 5.	Other Information	30

Item 6.	Exhibits	30

Signatures		31

This excerpt taken from the ABII 10-Q filed Nov 14, 2008.

INDEX


		Page
PART I. Financial Information

Item 1.	Financial Statements (Unaudited)	3

	Condensed consolidated balance sheets – September 30, 2008 and December 31, 2007	3

	Condensed consolidated and combined statements of operations – Three and nine months ended September 30, 2008 and 2007	4

	Condensed consolidated and combined statements of cash flows – Nine months ended September 30, 2008 and 2007	5

	Notes to unaudited condensed consolidated and combined financial statements – September 30, 2008	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	20

Item 4.	Controls and Procedures	21

PART II. Other Information

Item 1.	Legal Proceedings	21

Item 1A.	Risk Factors	22

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	32

Item 3.	Defaults Upon Senior Securities	32

Item 4.	Submission of Matters to a Vote of Security Holders	32

Item 5.	Other Information	32

Item 6.	Exhibits	32

Signatures		33

This excerpt taken from the ABII 10-Q filed Aug 14, 2008.

INDEX


		Page
PART I. Financial Information

Item 1.	Financial Statements (Unaudited)	3

	Condensed consolidated and combined balance sheets – June 30, 2008 and December 31, 2007	3

	Condensed consolidated and combined statements of operations – Three and six months ended June 30, 2008 and 2007	4

	Condensed consolidated and combined statements of cash flows – Six months ended June 30, 2008 and 2007	5

	Notes to unaudited condensed consolidated and combined financial statements – June 30, 2008	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	24

Item 4.	Controls and Procedures	25

PART II. Other Information

Item 1.	Legal Proceedings	26

Item 1A.	Risk Factors	26

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	36

Item 3.	Defaults Upon Senior Securities	36

Item 4.	Submission of Matters to a Vote of Security Holders	36

Item 5.	Other Information	36

Item 6.	Exhibits	36

Signatures		37

This excerpt taken from the ABII 10-Q filed May 15, 2008.

INDEX


		Page
PART I. Financial Information

Item 1.	Financial Statements (Unaudited)	3

	Condensed consolidated and combined balance sheets – March 31, 2008 and December 31, 2007	3

	Condensed consolidated and combined statements of operations – Three months ended March 31, 2008 and 2007	4

	Condensed consolidated and combined statements of cash flows – Three months ended March 31, 2008 and 2007	5

	Notes to unaudited condensed consolidated and combined financial statements – March 31, 2008	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	23

Item 4.	Controls and Procedures	24

PART II. Other Information

Item 1.	Legal Proceedings	25

Item 1A.	Risk Factors	25

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	39

Item 3.	Defaults Upon Senior Securities	39

Item 4.	Submission of Matters to a Vote of Security Holders	39

Item 5.	Other Information	39

Item 6.	Exhibits	39

Signatures		40

This excerpt taken from the ABII 10-Q filed Dec 20, 2007.

Exhibit Index


Exhibit Number		Description

2.1†		Separation and Distribution Agreement among Abraxis BioScience, Inc. (f/k/a Generico Holdings, Inc.), Abraxis BioScience, LLC, APP Pharmaceuticals, LLC and the Registrant

3.1†		Amended and Restated Certificate of Incorporation of the Registrant

3.2†		Amended and Restated Bylaws of the Registrant

3.3†		Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant

4.1†		Reference is made to Exhibits 3.1, 3.2 and 3.3

4.2		Specimen Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.2 to the Registrant’s Amendment #2 to Form 10 Registration Statement with the Securities and Exchange Commission on October 24, 2007)

4.3†		Registration Rights Agreement by and among the Registrant and certain stockholders of the Registrant as set forth therein

10.1†		Separation and Distribution Agreement among Abraxis Bioscience, Inc. (f/k/a Generico Holdings, Inc.), Abraxis BioScience, LLC, APP Pharmaceuticals, LLC and the Registrant (Filed as Exhibit 2.1 hereto)

10.2†		Tax Allocation Agreement among Abraxis Bioscience, Inc. (f/k/a Generico Holdings, Inc.), Abraxis BioScience, LLC, APP Pharmaceuticals, LLC and the Registrant

10.3†		Transition Services Agreement between Abraxis Bioscience, Inc. (f/k/a Generico Holdings, Inc.) and the Registrant

10.4†		Employee Matters Agreement among APP Pharmaceuticals, Inc. (f/k/a Generico Holdings, Inc. and Abraxis Bioscience, Inc.), APP Pharmaceuticals, LLC, Abraxis BioScience, LLC and the Registrant

10.5†*		Manufacturing Agreement between APP Pharmaceuticals, LLC and the Registrant

10.6†		Lease Agreement between APP Pharmaceuticals, LLC and Abraxis BioScience, LLC for the premises located at 2020 Ruby Street, Melrose Park, Illinois

10.7†		Lease Agreement between APP Pharmaceuticals, LLC and Abraxis BioScience, LLC for the warehouse facilities located at 2045 N. Cornell Avenue, Melrose Park, Illinois

10.8†		Lease Agreement between APP Pharmaceuticals, LLC and Abraxis BioScience, LLC for the research and development facility located at 2045 N. Cornell Avenue, Melrose Park, Illinois

10.9†		Lease Agreement between Abraxis BioScience, LLC and APP Pharmaceuticals, LLC for the premises located at 3159 Staley Road, Grand Island, New York

10.10		Form of Indemnification Agreement between the Registrant and each of its executive officers and directors (incorporated by reference to Exhibit 10.10 to the Registrant’s Amendment #1 to Form 10 Registration Statement with the Securities and Exchange Commission on October 5, 2007)

10.11		Employment Agreement, dated January 25, 2006, between the Registrant and Carlo Montagner (incorporated by reference to Old Abraxis’ Quarterly Report on Form 10-Q/A filed with the Securities and Exchange Commission on August 10, 2006)

10.12		Employment Agreement, dated July 3, 2006, between the Registrant and Lisa Gopalakrishnan (incorporated by reference to Old Abraxis’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2006)

10.13		Standard Form Office Lease, dated March 24, 2006, between the Registrant and California State Teacher’s Retirement System, as amended on May 26, 2006, for the premises located at 11755 Wilshire Boulevard, Los Angeles, California (incorporated by reference to Old Abraxis’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2006)


Exhibit Number		Description

10.14		Co-Promotion Strategic Marketing Services Agreement, dated April 26, 2006, between the Registrant and AstraZeneca UK Limited (incorporated by reference to Old Abraxis’ Quarterly Report on Form 10-Q/A filed with the Securities and Exchange Commission on August 10, 2006)

10.15†		Abraxis BioScience, Inc. 2007 Stock Incentive Plan, including forms of agreement thereunder

10.16		American BioScience, Inc. Restricted Stock Unit Plan I, including a form of agreement thereunder (incorporated by reference to Old Abraxis’ Registration Statement on Form S-8 (File No. 333-133364) filed with the Securities and Exchange Commission on April 18, 2006)

10.17		American BioScience, Inc. Restricted Stock Unit Plan II, including a form of agreement thereunder (incorporated by reference to Old Abraxis’ Registration Statement on Form S-8 (File No. 333-133364) filed with the Securities and Exchange Commission on April 18, 2006)

10.18		Agreement, dated April 18, 2006, between the Registrant and RSU LLC (incorporated by reference to Old Abraxis’ Quarterly Report on Form 10-Q/A filed with the Securities and Exchange Commission on August 10, 2006)

10.19*		Aircraft Purchase and Sale Agreement (incorporated by reference to Old Abraxis’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2006)

10.20		Escrow Agreement, dated April 18, 2006, by and among Abraxis BioScience, our chief executive officer and Fifth Third Bank (Incorporated by reference to Old Abraxis’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2006).

10.21*		License Agreement, dated as of May 27, 2005, between the Registrant and Taiho Pharmaceutical Co., Ltd. (incorporated by reference to Exhibit 10.10 to the Registrant’s Amendment #3 to Form 10 Registration Statement with the Securities and Exchange Commission on November 2, 2007)

10.22†		Agreement between APP Pharmaceuticals, Inc. (f/k/a Generico Holdings, Inc. and Abraxis BioScience, Inc.) and the Registrant

31.1†		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2†		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1†		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002

32.2†		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002

*	Certain portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the Securities and Exchange Commission.

†	Filed herewith.

EXCERPTS ON THIS PAGE:

10-Q	May 8, 2009

10-Q	Nov 14, 2008

10-Q	Aug 14, 2008

10-Q	May 15, 2008

10-Q	Dec 20, 2007

Abraxis BioScience (ABII)

ABII » Topics » INDEX

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

EXCERPTS ON THIS PAGE:

RELATED TOPICS for ABII:

"INDEX" elsewhere: